Interviews - Page 2

Keeping up with fast-paced clinical, regulatory, and policy innovation in healthcare is difficult. Our video interviews provide insight from key experts in the field of biosimilars, and help keep you informed.
Brian Lehman, MBA, MHA, RPh, director, Medical Account Management and Strategic Alliances, Sandoz, discusses the March 2020 transition of insulin to the biologics pathway.
Gillian Woollett, MA, DPhil, senior vice president, Avalere Health, discusses how  “confirmation of sufficient likeness" should replace “totality of evidence” in biosimilar development.
Cate Lockhart, PharmD, PhD, discusses the research reports the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) plans on releasing in 2020.
Tesh Khullar, senior vice president and advisor, Flatiron Health, discusses the impact biosimilars could make in community oncology.
Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses what she will be watching closely in the biosimilars space in early 2020.
Tesh Khullar, senior vice president and advisor, Flatiron Health, discusses challenges with reimbursement for biosimilars in community oncology practices.
Elaine Husni, MD, MPH, vice chair and director of the Arthritis and Musculoskeletal Center in the Orthopedic and Rheumatologic Institute at the Cleveland Clinic, discusses whether biosimilars are generating cost savings for patients with inflammatory diseases.
Rhett Wilkerson, associate director of patient financial services, Florida Cancer Specialists, discusses how utilization management strategies impact patient access to biologics. 
Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, discusses how patients are responding to using biosimilars.
Tesh Khullar, senior vice president and advisor, Flatiron Health, discusses biosimilar education for patients and providers.

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.